SillaJen, Inc. (KOSDAQ:215600)
South Korea · Delayed Price · Currency is KRW 2,035.00
+15.00 (0.74%)
Nov 2, 2026, 3:30 PM KST
SillaJen Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 10,772 | 9,225 | 3,927 | 3,940 | 5,013 | 254.36 |
Revenue Growth | 69.18% | 134.94% | -0.33% | -21.42% | 1870.95% | -84.77% |
Gross Profit Gross Profit Growth | 7,466 | 5,288 | 727.29 | 1,457 | 1,483 | 254.36 |
Operating Income Operating Income Growth | -26,115 | -25,576 | -26,703 | -21,472 | -24,447 | -20,378 |
Net Income Net Income Growth | -24,109 | -24,190 | -26,526 | -20,369 | -24,593 | -15,656 |
Earnings Per Share EPS Growth | -174.42 | -175.37 | -219.90 | -198.16 | -239.25 | -185.43 |
EPS Growth | - | - | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 |
Pharmaceutical Business Pharmaceutical Business Growth | 10,151 | 7,175 | - |
Other Product Sales Other Product Sales Growth | 620.55 | 2,051 | 3,927 |
Total Total Growth | 10,772 | 9,225 | 3,927 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 69,314 | 78,772 | 121,265 | 49,297 | 75,088 | 121,175 |
Total Debt Total Debt Growth | 1,401 | 2,265 | 10,689 | 9,697 | 15,216 | 16,772 |
Net Cash (Debt) Net Cash Growth | 67,913 | 76,507 | 110,576 | 39,600 | 59,872 | 104,403 |
Net Cash Growth | -24.38% | -30.81% | 179.23% | -33.86% | -42.65% | 1527.77% |
Net Cash Per Share Net Cash Per Share Growth | 491.31 | 554.65 | 916.70 | 385.25 | 582.46 | 1236.60 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -20,503 | -22,499 | -17,830 | -17,017 | -22,140 | -60,695 |
Capital Expenditures CapEx Growth | -94.5 | -246.32 | -221.46 | -351.43 | -291.7 | -64.57 |
Free Cash Flow Free Cash Flow Growth | -20,598 | -22,745 | -18,052 | -17,369 | -22,432 | -60,760 |
Free Cash Flow Growth | - | - | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 69.31% | 57.32% | 18.52% | 36.98% | 29.58% | 100.00% |
Operating Margin | -242.45% | -277.23% | -680.05% | -545.04% | -487.63% | -8011.50% |
Pretax Margin | -219.85% | -258.82% | -673.38% | -512.27% | -476.75% | -8698.00% |
Profit Margin | -223.82% | -262.21% | -675.53% | -517.04% | -490.55% | -6154.87% |
FCF Margin | -191.22% | -246.55% | -459.72% | -440.88% | -447.44% | -23886.96% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PS Ratio | 25.98 | 52.48 | 87.76 | 157.34 | 142.91 | 4889.81 |